Applications of Fluorescence Imaging Guided Lymph Node Dissection and Fluorescence Angiography of Inferior Mesenteric Artery Assisted Left Colic Artery Preservation
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06033794 |
Recruitment Status :
Recruiting
First Posted : September 13, 2023
Last Update Posted : September 13, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Fluorescence Indocyanine Green Rectal Cancer Surgery | Device: Fluorescence laparoscopic system | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Applications of Near-infrared Fluorescence Imaging Guided Lymph Node Dissection and Fluorescence Angiography of Inferior Mesenteric Artery Assisted Left Colic Artery Preservation: A Prospective Randomized Controlled Study |
Actual Study Start Date : | May 1, 2023 |
Estimated Primary Completion Date : | May 1, 2024 |
Estimated Study Completion Date : | May 1, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Laparoscopic No. 253 lymph node dissection and preserving the LCA under fluorescence guidance.
Preoperatively, indoycine green fluorescent dye was injected into the anus to trace the No. 253 lymph nodes, and intraoperatively, arterial branching of the mesentery was performed by intravenous injection of fluorescent dye to preserve the left colic artery.
|
Device: Fluorescence laparoscopic system
Intraoperative fluorescence imaging was performed using the DPM-ENDOCAM-03 and DPM-LIGHT-03 fluorescence imaging system (manufactured by Digital Precision Medicine Technology Co., Ltd., Zhuhai, China). This system provides original fluorescence mode, color mode, and fusion mode, allowing real-time quantitative analysis of the fluorescence signals. |
Active Comparator: Performing laparoscopic No. 253 lymph node dissection and preserving the LCA.
Conventional laparoscopic approach for dissection of the No. 253 lymph nodes and preservation of the left colic artery.
|
Device: Fluorescence laparoscopic system
Intraoperative fluorescence imaging was performed using the DPM-ENDOCAM-03 and DPM-LIGHT-03 fluorescence imaging system (manufactured by Digital Precision Medicine Technology Co., Ltd., Zhuhai, China). This system provides original fluorescence mode, color mode, and fusion mode, allowing real-time quantitative analysis of the fluorescence signals. |
- success rate of IMA fluorescence imaging [ Time Frame: From the beginning to the end of the surgery. ]ICG solution was prepared at a concentration of 2.5 g/L. A dose of 0.05 mg-0.10 mg/kg body weight of ICG was administered intravenously through a peripheral or central vein. Before the injection of ICG, the fluorescence laparoscope was set to the original fluorescence mode to monitor the IMA region in real-time.Record the success or failure rate of IMA fluorescence imaging in the observation group. Classify the successful IMA fluorescence imaging results into four different types according to the Morro classification and calculate the proportion of each type in successful imaging.
- Left colic artery retention rate [ Time Frame: From the beginning to the end of the surgery. ]Recording whether the left colic artery is preserved during surger.
- Incidence of IMA bleeding events [ Time Frame: From the beginning to the end of the surgery. ]Document incidents of mesenteric artery or vein bleeding caused by vascular injury during surgery.
- No.253 lymph node dissection time [ Time Frame: From the beginning to the end of the surgery. ]Measured based on surgical videos.
- Operation time [ Time Frame: From the beginning to the end of the surgery. ]Data obtained from anesthesia records.
- Intraoperative blood loss [ Time Frame: From the beginning to the end of the surgery. ]Data obtained from anesthesia records.
- Protective ostomy rate [ Time Frame: From the beginning to the end of the surgery. ]Data obtained from surgical records.
- Complication rate within 30 days after operation [ Time Frame: within 30 days after operation. ]According to the Clavien-Dindo classification system, complications were categorized into five grades. The postoperative status of each patient was recorded within 30 days, and the proportion of complications in each grade was calculated as a percentage of the total number of observations.
- Assessment of postoperative anal function urinary function within 30 days [ Time Frame: Assessment conducted once before surgery, on postoperative day 7, and on postoperative day 30. ]Evaluation of Low Anterior Resection Syndrome (LARS) scale, assessed using the following scales at preoperative, postoperative day 7, and day 30. Scores range from 0 to 42, with lower scores indicating better outcomes.
- Measurement of residual urine volume in the bladder. [ Time Frame: On the day the catheter was removed after surgery. ]Bladder residual urine volume was measured on the same day as catheter removal. A bladder residual urine volume of less than 50 ml was considered indicative of good bladder function, while a volume greater than or equal to 50 ml was considered indicative of urinary retention.
- Arterial development time [ Time Frame: From the beginning to the end of the surgery. ]Measured based on surgical videos.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients aged between 18 and 75 years
- Colonoscopic biopsy confirmed colorectal adenocarcinoma
- The tumor was located in the rectum or upper rectum, and the surgical method was Dxion
- No local complications before operation (no obstruction, incomplete obstruction, no massive active bleeding, no perforation, abscess formation, no local invasion)
- Preoperative imaging diagnosis was cT1-4aNxM0
- The hematopoietic functions of heart, lung, liver, kidney and bone marrow meet the requirements of surgery and anesthesia
- Sign the informed consent form
Exclusion Criteria:
- Previous surgical history of malignant colorectal tumors
- The surgical methods were combined abdominoperineal resection, Hartman operation and ISR operation
- There are contraindication of laparoscopic surgery, such as severe cardiopulmonary insufficiency
- Patients who have undergone multiple abdominal and pelvic surgeries or extensive abdominal adhesion
- Patients with intestinal obstruction, intestinal perforation, intestinal bleeding and other emergency operations
- ASA grade ≥IV and/or ECOG physical status score ≥2 points
- Patients with severe liver and kidney function, cardiopulmonary function, coagulation dysfunction or combined with serious underlying diseases can not tolerate surgery
- Have a history of serious mental illness
- Patients with uncontrolled infection before operation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06033794
Contact: Jianqiang Tang, Dr. | +8613661090036 | doc_tjq@hotmail.com |
China, Beijing | |
Cancer Hospital Chinese Academy of Medical Sciences | Recruiting |
Beijing, Beijing, China, 100021 | |
Contact: Jianqiang Tang, Dr. +8613661090026 doc_tjq@hotmail.com | |
Principal Investigator: Jianqiang Tang, Dr. |
Responsible Party: | Jianqiang Tang, Associate professor, Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
ClinicalTrials.gov Identifier: | NCT06033794 |
Other Study ID Numbers: |
NCC-4123 |
First Posted: | September 13, 2023 Key Record Dates |
Last Update Posted: | September 13, 2023 |
Last Verified: | September 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Left Colic Artery Fluorescence No. 253 lymph node Inferior mesenteric artery Indocyanine green |
Colic Infant, Newborn, Diseases |